Biogen’s first quarter results outpaced Wall Street’s expectations, prompting a positive market reaction. Management ...

RBC Capital Markets analysts believe Eli Lilly’s upcoming TRAILBLAZER-3 trial data on Kisunla could unlock a vast, largely untapped segment of the Alzheimer’s treatment market and pave the way for ...

Biogen is an intriguing stock that occupies one of the leading positions in the central nervous system therapeutic market. Read more on BIIB stock here.

Biogen shares slipped on Monday after the company said it expects to take a $46 million charge in the second quarter related ...

Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on ...

The EU has approved Eisai and Biogen's Leqembi for a subset of patients with early-stage Alzheimer's disease, more than two years after it was filed.

The drugs — Eli Lilly’s Kisunla (also known as donanemab) and Biogen and Eisai’s Leqembi (lecanemab) — won approval from U.K. regulators last year, with the Medicines and Healthcare ...

Acquisitions involving innovator drugs have grown year-on-year with total deal value increasing eight-fold to almost $18 ...

The FDA’s regular communications based on reports from its drug safety report database don’t always rattle investors’ cages.

Revenue Growth: Biogen's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 6.13%.

Diagnosing Alzheimer’s is difficult, and precise biomarkers are needed to assist physicians in making accurate assessments, ...